AV Sofosbuvir
(Die Seite wurde neu angelegt: „{{up|PHA antivirals by mechanism}} {{tp|p=32387040|t=ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug …“)
Zum nächsten Versionsunterschied →
Version vom 11. April 2021, 16:18 Uhr
| PHA antivirals by mechanism |
32387040 ä. Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?
32420958 2020. Sofosbuvir as a potential option for the treatment of COVID-19.
32419838 2020. Knowledge-based repositioning of the anti-HCV direct antiviral agent Sofosbuvir as SARS-CoV-2 treatment.
32518317 2020. Sofosbuvir as a potential alternative to treat the SARS-CoV-2 epidemic.
32812025 2020. Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial.
32812039 2020. Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial.
32812051 2020. The impact of sofosbuvir/daclatasvir or ribavirin in patients with severe COVID-19.
33063117 2020. Sofosbuvir/daclatasvir regimens for the treatment of COVID-19: an individual patient data meta-analysis.
